TY - JOUR
T1 - Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine
AU - Grinberg, Olga
AU - Gedanken, Aharon
AU - Mukhopadhyay, Debabrata
AU - Patra, Chitta Ranjan
PY - 2013/3
Y1 - 2013/3
N2 - Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over-expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti-EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico-chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti-EGFR (BSA-Gem-EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA-Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface.
AB - Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over-expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti-EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico-chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti-EGFR (BSA-Gem-EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA-Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface.
KW - Anti-EGFR monoclonal antibody
KW - BSA microspheres
KW - Gemcitabine
KW - Pancreatic cancer cells (AsPC1)
KW - Sonochemistry
KW - Targeted drug delivery
UR - http://www.scopus.com/inward/record.url?scp=84873568015&partnerID=8YFLogxK
U2 - 10.1002/pat.3081
DO - 10.1002/pat.3081
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84873568015
SN - 1042-7147
VL - 24
SP - 294
EP - 299
JO - Polymers for Advanced Technologies
JF - Polymers for Advanced Technologies
IS - 3
ER -